HBM and BioMap Announce Joint Venture to Establish MegaStream TechBio, a Global AI-Driven Drug Pipeline Company

　　【Pharmaceutical Network | Industry Dynamics] Since 2026, the deployment of AI in drug discovery has significantly accelerated, ranging from multinational pharmaceutical companies to domestic innovative drug enterprises. An increasing number of pharmaceutical companies have begun to elevate AI from an auxiliary R&D tool to a key engine driving innovation.
 

Recently, Harbour BioMed and BioMap jointly announced that they will co-establish a new AI-driven pipeline development company targeting the global market. The company will integrate “exclusive big data × proprietary large models × an extensive portfolio of innovative pipelines” to build an AI R&D engine centered on a next-generation intelligent dry-wet closed-loop experimental platform and personalized, multimodal, multi-attribute generative large models.
 

The platform will integrate Harbour BioMed’s proprietary experimental technologies with the technical advantages of BioMap’s BioMap OS discovery system in scheduling management, automated analysis, data management, and model iteration, thereby compressing the traditionally lengthy trial-and-error process into an efficient, precision screening workflow.
 

Industry insiders note that as AI-driven macromolecular drug development continues to gain momentum, the recent collaboration between Harbour BioMed and BioMap clearly demonstrates that AI is evolving from an “assistant” to a “helmsman.” Meanwhile, Harbour BioMed’s strategic initiatives in AI are expanding in scope. It is reported that Harbour BioMed had previously established “Nona Bioscience” as a preclinical AI technology platform, launched a fully human AI-generated HCAb model powered by the Hu-mAtrIx™ AI platform in October 2025, and initiated the Global AI + Biopharma Ecosystem Alliance.
 

Furthermore, in May this year, Harbour BioMed also released preclinical study data on its AI-derived drug candidate, the ActRIIA/B antibody LET003. The data indicated that LET003 exhibits superior pharmacokinetic properties, achieving lean body mass gains comparable to high-dose Bimagrumab at lower doses. When used in combination with semaglutide, it significantly enhances fat loss while effectively preserving lean body mass.
 

It is worth noting that, in addition to Harbour BioMed and BioMap, several other pharmaceutical companies have formed strategic alliances with AI firms this month, establishing “deeply integrated” partnerships to jointly build the underlying infrastructure for AI-driven drug discovery and accelerate the development of innovative therapies.
 

As reported on June 10, XtalPi announced that it has entered into a strategic AI-driven drug discovery collaboration with a well-known international biopharmaceutical company boasting a rich pipeline and multiple commercialized products. The total value of the partnership exceeds $400 million. The two parties will jointly develop innovative oral small-molecule drugs with best-in-class potential targeting a GPCR (G protein-coupled receptor). According to the agreement, the potential total value of the project exceeds $400 million.
 

In early June, small nucleic acid company Alnylam announced a strategic partnership with AI+mRNA startup Inceptive, valuing the collaboration at up to $2 billion. This partnership combines Alnylam’s RNAi platform and over 20 years of proprietary data with Inceptive’s foundational models and artificial intelligence expertise to drive and accelerate progress in nucleic acid-based drug design.
 

Overall, in the current pharmaceutical industry, AI is no longer limited to shortening specific R&D stages but has begun to participate in project design and R&D decision-making. In the future, as drug pipelines designed by AI enter clinical trials in large numbers, a more efficient and precise new paradigm for pharmaceutical development will accelerate its formation.
 

　　Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice to any person.